Company Filing History:
Years Active: 2024
Title: Innovations by Mark Berger in Hematologic Treatments
Introduction
Mark Berger is an accomplished inventor based in New York, NY, with a focus on innovative treatments for hematologic malignancies. He holds two patents that contribute significantly to the field of medicine, particularly in the treatment of complex hematological disorders.
Latest Patents
Berger's latest patents include methods for the treatment of patients with myelodysplastic syndromes. This invention outlines a method for treating a proliferative disease in hematologic malignancy by administering an effective amount of immunotherapy that targets the CD33 epitope. The treatment is applicable to various hematological diseases, including multiple myeloma and acute myeloid leukemia. Additionally, he has developed anti-CD45-based conditioning methods that involve depleting a subject's hematopoietic stem cells using a radiolabeled anti-CD45 antibody. This method is particularly useful for treating non-cancerous disorders through genetically edited cell therapy.
Career Highlights
Mark Berger is currently associated with Actinium Pharmaceuticals, Limited, where he applies his expertise in developing innovative therapies. His work has been instrumental in advancing treatment options for patients with complex hematological conditions.
Collaborations
Berger collaborates with notable colleagues, including Keisha Thomas and Sandesh Seth, to further enhance the impact of his inventions in the medical field.
Conclusion
Mark Berger's contributions to the field of hematologic treatments through his patents demonstrate his commitment to improving patient outcomes. His innovative approaches continue to pave the way for advancements in medical therapies.